March 28, 2005
Aller-7® TreatsAirborne Allergies
A multicenterclinical trial spanning three years and involving 545 patients with allergicrhinitis confirmed the safety and efficacy of Aller-7®, a patented nutritionalingredient from InterHealth Nutraceuticals (Int J ClinPharmacol Res, 24, 2-3:79-94, 2004). The study wascoordinated by the ASA Foundation. Researchers found over a period of 12 weeks,94 percent of patients in open label trials and 92 percent of patients in doubleblind, placebo-controlled trials treated with Aller-7 reported an improvement insymptoms ranging from 40 percent to 100 percent. In addition to relief fromsneezing, running nose and nasal congestion, improvement was also observed inabsolute eosinophil count, mucociliary clearance time and peak nasal flow rate. No serious side effects were reported.
Aller-7 is taken as a dietary supplement before allergyseason starts or even all year round, if perennial breathing difficulties are aproblem, making it an ideal long-term solution without debilitating sideeffects, said Skip Seroy, president of InterHealth(www.interhealthusa.com). Aller-7 is a patented blend of seven Indian herbal extracts,including Piper longum, Zingiberofficinale and Terminaliachebula.
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023